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Bone morphogenetic protein-9 suppresses growth of myeloma
cells by signaling through ALK2 but is inhibited by endoglin
OE Olsen1, KF Wader1,2, K Misund1, TK Va˚tsveen1, TB Rø1,3, AK Mylin4, I Turesson5, BF Størdal1, SH Moen1, T Standal1,6, A Waage1,7,
A Sundan1,6 and T Holien1
Multiple myeloma is a malignancy of plasma cells predominantly located in the bone marrow. A number of bone morphogenetic
proteins (BMPs) induce apoptosis in myeloma cells in vitro, and with this study we add BMP-9 to the list. BMP-9 has been found
in human serum at concentrations that inhibit cancer cell growth in vitro. We here show that the level of BMP-9 in serum was
elevated in myeloma patients (median 176 pg/ml, range 8–809) compared with healthy controls (median 110 pg/ml, range 8–359).
BMP-9 was also present in the bone marrow and was able to induce apoptosis in 4 out of 11 primary myeloma cell samples by
signaling through ALK2. BMP-9-induced apoptosis in myeloma cells was associated with c-MYC downregulation. The effects of
BMP-9 were counteracted by membrane-bound (CD105) or soluble endoglin present in the bone marrow microenvironment,
suggesting a mechanism for how myeloma cells can evade the tumor suppressing activity of BMP-9 in multiple myeloma.
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INTRODUCTION
The hematological cancer multiple myeloma arises from terminally
differentiated plasma cells and is primarily found in the bone
marrow.1 Some cytokines in the bone marrow induce apoptosis in
myeloma cells. We and others have earlier shown that bone
morphogenetic proteins (BMP)-2, -4, -5, -6 and -7 induce growth
arrest or apoptosis in myeloma cells in vitro.2–5 Furthermore, high
expression of BMP-6 in myeloma cells correlated positively with
overall survival of multiple myeloma patients.6 BMPs may therefore
act as tumor suppressors inhibiting myeloma development.
Multiple myeloma is usually associated with severe osteolytic
lesions due to a disturbed balance between bone formation
and resorption. In addition to the growth inhibitory effects
on myeloma cells, BMPs mediate osteogenic differentiation of
mesenchymal stem cells and promote bone formation.7 BMP-9 is
one of the least characterized BMPs; nevertheless it may be one of
the most potent BMPs in inducing osteogenic differentiation.8,9
On the other hand, BMP-9 protected monocyte-derived
osteoclasts from apoptosis.10 BMP-9 was present in biologically
active concentrations (2–12 ng/ml) in serum of healthy indivi-
duals.11,12 In humans, BMP-9 was found to be produced
predominantly in the liver.13 BMP9 mRNA has also been found
to be expressed in human bone cells.14
BMPs may signal through four type I receptors (ALK1, ALK2,
ALK3 and ALK6) and three type II receptors (BMPRII, ActRIIA
and ActRIIB).15 BMP-9 and -10 are the only known BMPs that bind
the type I BMP-receptor ALK1, predominantly expressed by
endothelial cells.16 However, in addition to signaling through
ALK1, BMP-9 has also been shown to signal through ALK2.15,17
Multiple myeloma cells do not express ALK1, but 85% of primary
myeloma cells express ALK2 mRNA.6,18 The role of BMPs in cancer
is somewhat unclear, but BMP-9 and -10 have been reported to
exert tumor suppressing activities in both breast and prostate
cancer.19–22 In contrast, autocrine BMP-9 signaling supported
proliferation of ovarian as well as liver cancer cells.17,23
Endoglin (CD105) is an accessory receptor for the TGF-b family of
ligands. BMP-9 and -10 are the only known ligands that bind
endoglin directly,24,25 whereas endoglin can bind TGF-b, activin-A,
BMP-2 and BMP-7 in complex with their respective receptors.26
Membrane-bound endoglin is necessary for TGF-b signaling through
ALK1 and has been proposed to balance signaling through either
ALK1, promoting proliferation, or through ALK5, which inhibits
growth of endothelial cells.27 Endoglin is highly expressed by
endothelial cells at sites of active angiogenesis28 and elevated levels
were found in myeloma bone marrow,29 as well as in tumors such as
breast, colon, brain, lung, prostate and cervical cancer (reviewed in
Duff et al.30). Moreover, BMP-9 inhibited migration and proliferation
of endothelial cells, as well as angiogenesis.11,25
A soluble form of endoglin is shed from cells and its levels have
been found to be elevated in various cancers and correlated
with metastatic disease.31–33 It was reported that serum levels
of endoglin were higher in multiple myeloma patients than in
healthy controls and that high levels were associated with
advanced disease, tumor growth and angiogenesis.34,35
Here we show that BMP-9 induced apoptosis in multiple
myeloma cells by signaling through ALK2, and that soluble as well
as membrane-bound endoglin protected myeloma cells from
BMP-9-induced apoptosis.
MATERIALS AND METHODS
Cell lines and reagents
The human multiple myeloma cell lines INA-6, ANBL-6, CAG and JJN-3
were kind gifts from Dr M Gramatzki (University of Erlangen-Nurnberg,
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Erlangen, Germany), Dr D Jelinek (Mayo Clinic, Rochester, MN, USA),
Dr J Epstein (University of Arkansas for Medical Sciences, Little Rock, AR, USA)
and Dr J Ball (University of Birmingham, Birmingham, UK), respectively.
RPMI-8226 and U266 were from American Type Culture Collection
(Rockville, MD, USA). IH-13 and KJON were established in our laboratory.
INA-6 and ANBL-6 cells were grown in 10% heat-inactivated fetal calf
serum in RPMI-1640 (RPMI) supplemented with recombinant human
interleukin (IL)-6 (1 ng/ml). IH-1 cells were maintained in 10% heat-
inactivated human serum (Department of Immunology and Transfusion
Medicine, St Olav’s University Hospital, Trondheim, Norway) in RPMI and
IL-6 (2 ng/ml). CAG, JJN-3, RPMI-8226 and U266 were grown in RPMI
supplemented with 10%, 10%, 20% or 15% fetal calf serum, respectively.
Cells were cultured at 37 1C in a humidiﬁed atmosphere containing 5%
CO2. For experiments, 2% human serum in RPMI was used as medium, with
IL-6 (1 ng/ml) added for IL-6-dependent cells. All recombinant human
proteins were from R&D Systems (R&D Systems Europe Ltd., Abingdon,
UK), except IL-6 (Biosource, Camarillo, CA, USA).
Primary cells
To obtain primary myeloma cells, CD138þ cells were isolated from bone
marrow specimens obtained through the Norwegian Myeloma Biobank
using RoboSep automated cell separator and the Human CD138 Positive
Selection Kit (StemCell Technologies, Grenoble, France). The study was
approved by the regional ethics committee (2011/2029) and all patients
had given informed consent. Bone marrow stromal cells (BMSCs) were
prepared as earlier described.36
Cell viability and proliferation
Cells were stained using the Apotest FITC kit (Nexins Research, Kattendijke,
The Netherlands). Brieﬂy, cells were incubated with annexin V ﬂuorescein
isothiocyanate (0.2mg/ml) on ice for 1 h. Propidium iodide (PI) (1.4mg/ml)
was added 5min before cells were analyzed using an LSRII ﬂow cytometer
(BD Biosciences, San Jose, CA, USA). Cells negative for both annexin V and
PI staining were considered viable. CellTiter-Glo (Promega, Madison, WI,
USA) measures ATP levels in cells by use of luciferase and was used to
determine relative cell proliferation. Cells were seeded in 96-well optical
plates and treated as indicated. CellTiter-Glo reagent was added according
to the manufacturer’s protocol and luminescence was determined using
Victor 1420 multilabel counter (PerkinElmer Inc., Waltham, MA, USA).
Cell cycle analysis
JJN-3 cells were seeded at 200 000 cells/ml and cultured for 18 h with or
without BMP-4, BMP-6 or BMP-9. A modiﬁed version of the Vindeløv
method was used to prepare nuclei for ﬂow cytometric DNA analysis, and
is described elsewhere.37,38 Data was acquired with an LSRII ﬂow cytometer
(BD) and analyzed in FlowJo (Tree Star, Inc., Ashland, OR, USA) using the
Watson pragmatic model.
Immunoblotting
Cells were treated as indicated, washed with ice cold phosphate-buffered
saline (PBS) and lysed for 15min on ice. The lysis buffer contained 1%
Nonidet P40 (NP-40) (Sigma-Aldrich, St Louis, MO, USA), 150mM NaCl,
50mM Tris-HCl (pH 7.5), protease inhibitor cocktail (Roche, Basel, Switzerland),
1mM Na3VO4 and 50mM NaF. Samples were electrophorated on
NuPAGE Bis-Tris gels with MOPS running buffer (Invitrogen, Carlsbad,
CA, USA). Gels were blotted onto nitrocellulose membranes, blocked with
5% nonfat dry milk in Tris-buffered saline with 0.01% Tween 20 (TBS-T)
and incubated overnight with primary antibodies as indicated. Primary
antibodies used were: c-MYC (BD Norge AS, Trondheim, Norway),
phospho-SMAD1/5/8 (Cell Signaling Technology, Medprobe, Oslo, Norway),
endoglin (Santa Cruz Biotechnology, Inc., Heidelberg, Germany) and
GAPDH (Abcam, Cambridge, UK). Blots were washed in TBS-T before
incubation for 1 h with horseradish peroxidase-conjugated secondary
antibodies (Dako Cytomation, Glostrup, Denmark). The blots were washed
thoroughly with TBS-T before bands were detected using SuperSignal West
Femto (Thermo Fisher Scientiﬁc, Waltham, MA, USA) as luminescence
substrate and Kodak Image Station 2000R (Kodak, Rochester, NY, USA).
Quantitative reverse transcription-PCR
Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen,
Crawley, UK) and complementary DNA was synthesized from total
RNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems,
Carlsbad, CA, USA). PCR was performed using StepOne Real-Time
PCR System and Taqman Gene Expression Assays (Applied Biosystems).
The Taqman assays used were: ALK1/ACVRL1 (Hs00163543_m1),
ALK2/ACVR1 (Hs00153836_m1), ALK3/BMPR1A (Hs01034909_g1), ALK6/
BMPR1B (Hs00176144_m1), ActRIIA/ACVR2A (Hs00155658_m1), ActRIIB/
ACVR2B (Hs00609603_m1), BMPRII/BMPR2 (Hs00176148_m1), ENG
(Hs00923997_g1), GAPDH (Hs99999905_m1) and ID1 (Hs00357821_g1).
The comparative Ct method was used to estimate relative changes in gene
expression using GAPDH as housekeeping gene.
Transfections
Myeloma cell lines were transfected using the Nucleofector device
(Amaxa biosystems, Cologne, Germany) and the Amaxa Nucleofector Kit
R for INA-6 or T for CAG (Lonza, Basel, Switzerland), as previously
described.39 For each transfection, cells were treated with 1 mM ON-
TARGETplus Non-Targeting pool, SMARTpool ACVR1 or ENG siRNAs
(Dharmacon RNAi technologies by Thermo Scientiﬁc, Lafayette, CO, USA).
Cytokine measurements
Patient serum samples were collected for the Nordic Myeloma Study
Group during a randomized phase 3 clinical trial on pamidronate dosage in
the years 2001–2005.40 Only samples that were taken before start of
treatment were included (n¼ 138). For comparison, serum was collected
from 58 age- and gender-matched healthy volunteers. Bone marrow
plasma samples from 16 patients were also obtained as described.41 The
presence of BMP-9 and soluble endoglin in bone marrow plasma and cell
culture supernatants was assayed using human BMP-9 and endoglin/
CD105 DuoSet ELISAs (R&D Systems). Serum samples were analyzed using
a multiplex assay (MILLIPLEX MAP Human Angiogenesis/Growth Factor
Magnetic Bead Panel, HAGP1MAG-12K, Millipore Corporation, Billerica, MA,
USA) for determination of BMP-9. For measurements of soluble endoglin in
serum, the DuoSet ELISA was used. All samples were run in duplicates and
values above or below the standard curves were set to the highest or
lowest standard value, respectively.
Endoglin cell membrane expression
Myeloma cells and BMSCs were washed with PBS containing 0.1% bovine
serum albumin (BSA) (PBS/BSA). Cells were then labeled with phyco-
erythrin-conjugated antibodies: isotype control or endoglin (CD105) (BD
Norge AS). After 20min of incubation, cells were washed with PBS/BSA and
resuspended in PBS. Data were acquired using an LSRII ﬂow cytometer and
analyzed using FlowJo software.
Coculture experiments
For cocoulture experiments a method applying an automated ﬂuorescence
microscope platform was used.36 Brieﬂy, BMSCs were allowed to adhere to
96-well plates before INA-6 cells and BMPs were added. Cell membrane
integrity was evaluated as a measure of viability using YO-PRO-1 DNA stain
(Invitrogen) that labels apoptotic cells. Myeloma cells and BMSCs were
distinguished by size, shape and intensity of DRAQ5 nuclear staining
(eBioscience, San Diego, CA, USA). The ScanR microscope-based screening
platform was used for automated image acquisition and images were
analyzed using the Olympus ScanR Analysis software (Olympus, Hamburg,
Germany).
Statistics
Statistical calculations were done using IBM SPSS Statistics 20 (IBM Corp.,
Armonk, NY, USA). For serum samples, all patients were included, except
for analysis of progression-free survival where 18 patients were omitted
due to missing data. Comparisons between groups were done using
Mann–Whitney U-test. Survival analysis was done by the Kaplan–Meier
method. Correlations were analyzed using Spearman’s rank correlation
test. The level of statistical signiﬁcance was Po0.05 (two-tailed).
RESULTS
BMP-9 induced apoptosis and growth arrest in myeloma cell lines
and primary cells
To determine whether BMP-9 could induce apoptosis in myeloma
cells, the eight myeloma cell lines INA-6, ANBL-6, CAG, KJON, IH-1,
RPMI-8226, U266 and JJN-3 were treated with BMP-9 before cell
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viability was measured using annexin V labeling. The INA-6 and
IH-1 cell lines were highly sensitive toward BMP-9-induced
apoptosis (Figure 1a). BMP-9 also induced apoptosis in the
myeloma cell lines RPMI-8226 and KJON, whereas in the remaining
four cell lines no effect of BMP-9 on apoptosis was observed
(Figure 1b). We have earlier shown that BMP-induced apoptosis in
myeloma cells was dependent on downregulation of c-MYC.5,42
Likewise, BMP-9 also induced c-MYC downregulation in a dose-
dependent manner in INA-6 cells (Figure 1c).
Earlier we observed that the JJN-3 cell line was growth arrested
by BMP-4 or BMP-6 treatment, whereas there was no effect on
apoptosis (Supplementary Figure 1). Similarly, after 24 h of BMP-9
treatment a signiﬁcant proportion of the JJN-3 cells were arrested
in the G1-phase of the cell cycle as compared with control cells
(Figure 1d).
We also chose to study growth inhibition in myeloma cells
by quantifying intracellular ATP levels as a measure of relative cell
proliferation (Figure 1e). The INA-6 and IH-1 cell lines were growth
inhibited by BMP-9 at concentrations o0.5 ng/ml, whereas CAG
and U266 were not affected even at a concentration of 50 ng/ml
BMP-9. The other cell lines showed varying degrees of sensitivity
to BMP-9. Taken together, we concluded that of the cell lines
tested here, two were resistant (CAG and U266) and two were only
growth arrested (JJN-3 and ANBL-6), whereas the remaining four
became apoptotic and/or growth arrested following treatment
with BMP-9.
BMP-9 and -10 are highly homologous and both have
been shown to suppress breast and prostate cancer cells.19–22
We therefore tested whether also BMP-10 had an effect on
myeloma cells. However, even at a concentration of 400 ng/ml no
effect of BMP-10 on apoptosis or growth arrest in INA-6 and IH-1
cells was seen (data not shown).
Finally, we treated isolated CD138þ cells from 11 myeloma
patients with BMP-9 (5 ng/ml). A signiﬁcant reduction in cell
viability of at least 15% compared with untreated cells was seen in
4 out of 11 samples (Figure 1f), indicating that BMP-9 induces
apoptosis also in some primary myeloma cell samples.
BMP-9 signaled through ALK2 in myeloma cells
The observation that BMP-9 had a strong effect on myeloma cells,
whereas BMP-10 had no effect, suggested that BMP-9 signaled
through another BMP type I receptor than the common BMP-9/10
receptor ALK1 in these cells.
Indeed, primary myeloma cells did not express ALK1 mRNA
(Figure 2a). In contrast, they all contained mRNA encoding the
BMP type I receptors ALK2, ALK3 and in some cases also ALK6. The
three type II receptors BMPRII, ActRIIA and ActRIIB were expressed
in all primary myeloma cell samples. Interestingly, ALK2, as well as
all BMP type II receptors, has been reported to bind BMP-9.15
Using quantitative reverse transcription-PCR we found that INA-6
cells express ALK2, barely detectable levels of ALK3 and no ALK6
(data not shown). To show that BMP-9 actually signaled through
ALK2 in myeloma cells, we ﬁrst incubated cells with dorsomorphin
homolog 1, an inhibitor of BMP-receptor-activated SMADs.43 The
inhibitor counteracted BMP-9-induced apoptosis in INA-6 as well
Figure 1. BMP-9-induced apoptosis and growth arrest in myeloma cells. (a, b) Human myeloma cell lines were treated for 3 days with the
indicated concentrations of BMP-9. Cell viability was assessed by flow cytometry following annexin V fluorescein isothiocyanate and
propidium iodide (PI) labeling. Cells that were negative for annexin V and PI were considered viable. (c) INA-6 cells were treated for 20 h with
the indicated concentrations of BMP-9, subjected to cell lysis, electrophoresis and immunoblotting with antibodies detecting c-MYC,
phosphorylated SMAD1/5/8 or GAPDH. (d) JJN-3 cells were treated with BMP-9 for 24 h and subjected to cell cycle analysis. (e) Human
myeloma cell lines were treated for 3 days with the indicated concentrations of BMP-9. Cell growth was evaluated using CellTiter-Glo. Relative
luciferase units (RLU) reflected the amount of ATP in each well. (f ) CD138þ cells from patients were treated with BMP-9 (5 ng/ml) for 3 days
before cell viability was measured as described in (a). The data in a–d are representative of three independent experiments, whereas
experiments using primary cells (f ) were performed once. Data are presented as means±1 s.d. Asterisks (b, f ) indicate a significant lower cell
viability of at least 15% compared with control (Po0.05, one-tailed t-test).
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as in IH-1 cells (Supplementary Figure 2), indicating that, as with
other BMPs, also BMP-9-induced apoptosis was dependent on
activation of BMP-receptor-activated SMADs. Knockdown experi-
ments were then performed in the INA-6 cell line using ALK2 small
interfering RNA (siRNA). INA-6 cells transfected with ALK2 siRNA
showed a reduction of ALK2 mRNA levels to B40% of control
levels (Figure 2b). Two days post transfection, INA-6 cells were
incubated with or without BMP-9 for 1 h. Pre-treatment with ALK2
siRNA reduced the level of BMP-9-induced SMAD1/5/8 phosphor-
ylation as determined by immunoblotting (Figure 2c). Further-
more, to determine whether the function of activated SMAD1/5/8
was affected, we looked at the well-known SMAD target gene
ID1.44 The relative amounts of ID1 mRNA were determined by
quantitative reverse transcription-PCR in cells treated with BMP-9.
The BMP-9-induced increase of ID1 mRNA was signiﬁcantly
reduced in cells treated with ALK2 siRNA as compared with
non-targeting control siRNA (Figure 2d). BMP-6 also used ALK2 for
activation of SMAD1/5/8 in INA-6 cells (Supplementary Figure 3).
We have earlier shown that BMP-induced apoptosis in myeloma
cells occurs through SMAD-dependent downregulation of
c-MYC.5 BMP-9-induced downregulation of c-MYC was indeed
counteracted by the use of ALK2 siRNA (Figure 2e). In summary,
our results clearly indicate that ALK2 is the BMP type I receptor
used for BMP-9 signaling in myeloma cells.
Soluble and membrane-bound endoglin sequestered BMP-9 and
antagonized the growth inhibitory effects of BMP-9
Betaglycan and endoglin are auxiliary, type III receptors of the
TGF-beta superfamily, and BMP-9 has previously been shown to
bind endoglin even in the absence of BMP receptor.24,25 To clarify
whether type III receptors were able to inﬂuence BMP-9 signaling
in myeloma cells, we incubated cells with BMP-9 in the absence or
presence of soluble recombinant human betaglycan or endoglin.
Betaglycan had no effect on BMP-9 signaling under the given
conditions (data not shown). Endoglin, on the other hand,
antagonized BMP-9 signaling in a dose-dependent manner
(Figure 3a). INA-6 cells express the type I receptor ALK2 and
minute amounts of ALK3, and are not responsive to BMP-2, -4 or -5
that signal through ALK3 (Ro et al.4 and data not shown). Thus,
only BMP-6, -7 and, as shown here, BMP-9 have reported effects
on INA-6 cells. To determine the effects of endoglin on other
BMPs, we therefore chose to use IH-1 cells that express all known
type I receptors, except for ALK1, and which is generally sensitive
to BMPs.4 Addition of soluble endoglin did not affect BMP-2-,
-4- or -6-induced apoptosis in IH-1 cells (Figure 3b), indicating
that endoglin inhibits BMP-9, but not BMP-2, BMP-4 or BMP-6.
The inhibitory effect of soluble endoglin on BMP-9-induced
apoptosis was also seen in primary myeloma cells from patient
MM2 and MM5 (Figure 3c).
We also tested the effects of the recombinant human
antagonists such as chordin-like 1, crossveinless-2, follistatin,
gremlin and twisted gastrulation on BMP-9 signaling. Chordin-like
1 and twisted gastrulation counteracted the effect of BMP-9 on
INA-6 proliferation, but only when used at 10 mg/ml (Supple-
mentary Figure 4). The other antagonists had no signiﬁcant
effects, suggesting that there are few naturally occurring
antagonists of BMP-9.
We further hypothesized that presence of endoglin in the bone
marrow microenvironment could be one way for myeloma cells
to evade BMP-9-induced apoptosis. Measurements of soluble
endoglin and BMP-9 in bone marrow plasma from 16 myeloma
Figure 2. BMP-9 signaled through ALK2 in myeloma cells. (a) Comparison of the expression of different BMP receptors in 11 patient samples.
The relative levels of mRNA were determined by quantitative reverse transcription (QRT)-PCR and compared with the expression of ActRIIA in
patient MM2, which was set to 1. (b) QRT-PCR showing knockdown of ALK2 mRNA in siRNA-treated INA-6 cells. The cells were transfected with
either Non-Targeting control or ALK2 siRNA and cells were collected at day 2 post transfection. (c) Transfected INA-6 cells were treated 2 days
post transfection with BMP-9 (0.5 ng/ml) for 1 h and subjected to immunoblotting with antibodies detecting phosphorylated SMAD1/5/8 or
GAPDH. (d) Cells treated as in (c) and analyzed for expression of ID1 mRNA by QRT-PCR. (e) INA-6 cells transfected as in (b). Cells were treated
with or without BMP-9 for 20 h and subjected to immunoblotting with antibodies detecting c-MYC or GAPDH. Error bars represent 1 s.d. RQ,
relative quantitation.
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patients showed presence of both soluble endoglin (median
14.1 ng/ml, range 9–22) and BMP-9 (median 33.9 pg/ml, range
5–160). These data indicate that soluble endoglin is present in the
bone marrow at a level that inhibits BMP-9-induced apoptosis in
myeloma cells, as shown in Figure 3a.
A potentially important source of endoglin in the bone marrow
is membrane-bound endoglin. Membrane-bound endoglin was
present on 495% of expanded BMSCs from myeloma patients
(Figure 3d). Interestingly, BMSCs protected INA-6 cells from BMP-9-
induced apoptosis, but not BMP-6-induced apoptosis (Figure 3e),
consistent with the ﬁnding that endoglin binds BMP-9 but not
BMP-6.
Some myeloma cell lines were unresponsive to BMP-9-induced
growth inhibition (Figure 1). Having also shown that endoglin is
Figure 3. Endoglin inhibited BMP-9, but not BMP-2, BMP-4 or BMP-6. (a) INA-6 cells were treated for 3 days with indicated concentrations of
BMP-9 in the presence of increasing amounts of recombinant human soluble endoglin. Relative cell growth was measured using the CellTiter-
Glo assay. (b) IH-1 cells were treated for 3 days with BMP-2 (200 ng/ml), BMP-4 (20 ng/ml), BMP-6 (300 ng/ml) or BMP-9 (5 ng/ml) in the
presence of increasing amounts of soluble endoglin. Cell viability was measured by annexin V and PI staining. (c) Myeloma cells from patient
MM2 and MM5 were treated with BMP-9 (5 ng/ml), endoglin (1mg/ml) or a combination of both for 3 days before cell viability was measured
using annexin V and PI. Untreated cells were used as control. (d) BMSCs were incubated with PE-labeled endoglin or isotype control antibodies
and analyzed by flow cytometry. (e) INA-6 cells were grown in coculture with increasing numbers of BMSCs in the presence of BMP-9 (0.25ng/ml)
or BMP-6 (50 ng/ml). Cell membrane integrity was evaluated as a measure of viability using the YO-PRO-1 DNA stain as described in the
Materials and Methods section. (f ) QRT-PCR showing knockdown of endoglin (ENG) mRNA in siRNA-treated CAG cells. The cells were
transfected with either Non-targeting Control or ENG siRNA and cells were collected 2 days post transfection. (g) Transfected CAG cells were
treated 2 days post transfection with BMP-9 (0.5 ng/ml) for 1 h and subjected to immunoblotting with antibodies detecting phosphorylated
SMAD1/5/8, endoglin or GAPDH. (h) CAG cells treated as in (f ) and analyzed for expression of ID1 mRNA by QRT-PCR. Error bars represent 1
s.d. RQ, relative quantitation.
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capable of inhibiting BMP-9, we hypothesized that one way in
which myeloma cells could be protected from BMP-9-induced
growth inhibition was by expressing endoglin on their cell surface.
In contrast to INA-6 cells, CAG cells express endoglin
(Supplementary Figure 5). To further explore the role of endoglin
in BMP-9 signaling, we knocked down endoglin in the CAG cell
line using siRNA transfection. Knockdown of endoglin (Figures 3f
and g) led to increased BMP-9 signaling, as shown directly by
immunoblot showing increased phosphorylation of SMAD1/5/8
(Figure 3g) and indirectly by quantitative reverse transcription-
PCR showing increased BMP-9 mediated induction of SMAD-
responsive ID1 (Figure 3h).
To summarize, these results suggest that myeloma cells in the
bone marrow may be protected from BMP-9-induced growth
suppression or apoptosis by endoglin expressed on myeloma or
BMSC surfaces, or endoglin in a soluble form.
Soluble endoglin and BMP-9 were also measured in
serum from a larger patient group (n¼ 138) and compared with
levels in serum from healthy individuals (n¼ 58). Median
serum BMP-9 concentration in myeloma patients (176 pg/ml,
range 8–809) was signiﬁcantly higher (P¼ 0.002) than in healthy
controls (110 pg/ml, range 8–359) (Figure 4a). We found no
signiﬁcant increase in the levels of soluble endoglin in myeloma
patients (20.2 ng/ml, range 10.4–40.0) compared with healthy
controls (21.9 ng/ml, range 14.8–40.0) (Figure 4b). Neither
BMP-9 nor soluble endoglin levels had any inﬂuence on overall
survival or progression-free survival (data not shown). We also
analyzed the data to see whether there were any correlations
between BMP-9 or endoglin and the percentage of plasma cells
in bone marrow, serum levels of M-protein, b2-microglobulin
or albumin, disease stage (International Staging System)
or bone disease. Only minor correlations were found between
serum levels of BMP-9 and M-protein and albumin (data not
shown).
DISCUSSION
Many BMPs are potent inhibitors of myeloma cell growth in vitro,
causing growth arrest or apoptosis in a number of cell lines and
primary cells. However, some cells evade the growth inhibitory
effects of BMPs, as was also the case here with BMP-9. There are
several possible reasons for this, and one obvious reason would be
lack of appropriate receptors. For BMPs to exert their growth
inhibitory functions on myeloma cells, they must bind speciﬁc
BMP receptors to induce phosphorylation of receptor-activated
SMADs; SMAD1/5/8.5 Myeloma cells in general express all known
BMP receptors, except ALK1. There are some variations,
particularly in expression of ALK6, where detectable levels were
found in 5 out of 11 patient samples tested here. Nevertheless,
even when BMPs bind correctly and induce activation of SMADs,
the cells may evade growth inhibition. In line with this, we found
no correlation between expression of ALK2 and BMP-9 sensitivity
in primary myeloma cells. Myeloma cells could also possibly evade
growth inhibitory effects of BMP by defect SMAD1/5/8 function
after phosphorylation by cyclin-dependent kinases, as described
for TGF-b activated SMAD2.45 Other ways that may render
cells resistant to BMP-induced growth inhibition are lack of
downstream components of the SMAD-signaling pathway, as
shown in lymphoma cells.46 Owing to scarcity of material, we
chose to use one concentration of BMP-9 (5 ng/ml) when
analyzing primary cells. Using this concentration, 4 out of 11
samples showed a signiﬁcant downregulation of cell viability by at
least 15% as compared with control. The effects of BMP-9 are dose
dependent, thus from these analyses it is not possible to tell if
more patient samples would be sensitive if higher concentrations
of BMP-9 had been used.
We have earlier shown that BMP induced apoptosis in myeloma
cells by downregulation of c-MYC and that myeloma cells depend
on c-MYC for survival.5,42 Also in the case of BMP-9, cell death
correlated with downregulation of c-MYC protein, underscoring
the importance of c-MYC expression for myeloma cell survival.
Moreover, translocations placing MYC in the proximity of
immunoglobulin enhancers may be one of the ways myeloma
cells become resistant to BMP-induced apoptosis.5
The BMP ligand–receptor interaction is highly promiscuous; one
receptor can bind different ligands, whereas one ligand can
activate different sets of receptors. Previous studies have shown
that BMP-9 signals by binding to the type I receptors ALK1 and
ALK2. The binding to ALK1 is stronger than the binding to ALK2,
and binding of BMP-9 to ALK2 is strongly enhanced in the
presence of type II receptors.25 Indeed, using a panel of
recombinant human BMP receptors, we found that ALK1
completely blunted BMP-9-induced growth inhibition on INA-6
cells, whereas ALK2 had no detectable effect (data not shown).
We show for the ﬁrst time that serum levels of BMP-9
are increased in myeloma patients compared with healthy
controls. Soluble endoglin was previously found to be increased
in myeloma sera and correlated with advanced stages of the
disease.34 In our material we could not ﬁnd a signiﬁcant increase
in serum levels of soluble endoglin in myeloma patients compared
with healthy controls. Nevertheless, we show that soluble
endoglin is also present in the bone marrow of myeloma
patients at levels that inhibit BMP-9-induced apoptosis in
Figure 4. Serum concentrations of BMP-9 and soluble endoglin.
The concentrations of BMP-9 (a) and soluble endoglin (b) were
measured in serum samples from 138 patients and 58 healthy
controls. The dark lines indicate median concentrations. Outliers and
extreme outliers are indicated by points and asterisks, respectively.
The top of the box represents the 75th percentile, whereas the
bottom represents the 25th percentile.
Endoglin inhibits BMP-9-induced apoptosis
OE Olsen et al
6
Blood Cancer Journal & 2014 Macmillan Publishers Limited
myeloma cells. We found that myeloma-derived BMSCs express
membrane-bound endoglin, but there is also an increased amount
of endoglin-expressing endothelial cells in the bone marrow
of myeloma patients compared with healthy controls.29 These,
and other sources of endoglin, may scavenge BMP-9 from the
surroundings of myeloma cells, thereby protecting them from the
growth inhibitory effects of BMP-9. Interestingly, endoglin
expressed on the surface of myeloma cells also inhibited BMP-9
signaling, as shown by knockdown experiments in CAG cells. Thus,
targeting endoglin using neutralizing antibodies could represent a
promising approach for myeloma treatment.
In conclusion we here show that myeloma cells can be growth
arrested or killed by low doses of BMP-9, and that the effects of
BMP-9 is mediated by ALK2 in these cells. BMP-9, together
with the previously described BMP-2, -4, -5, -6 and -7, thus has the
potential to counteract myelomagenesis in the bone marrow, and
for the ﬁrst time we show that BMP-9 is increased in myeloma
patient serum compared with healthy controls. The cellular source
for BMP-9 remains to be investigated. We also present data
indicating that BMP-9, in contrast to BMP-2, -4 or -6, may be
scavenged by soluble as well as membrane-bound endoglin. Thus,
endoglin may regulate the availability of this cytokine for
myeloma cells in the bone marrow microenvironment and could
be a promising target for therapy.
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